BioMarin Pharmaceutical Inc. (BMRN) Income Statement
BMRN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBMRN revenue and net income
Where BMRN's revenue goes
2025Each bar shows an amount and its share of revenue. BMRN kept 10.8% of revenue as net income.
BMRN profit margins
BMRN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +12.9% | +15.4% | +11.6% | +13.7% |
| Gross profit | +9.3% | +16.0% | +13.2% | +12.9% |
| Operating income | +10.2% | +49.1% | — | — |
| Net income | −18.3% | +35.1% | −16.4% | — |
| EPS (diluted) | +0.3% | +26.1% | +17.9% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BMRN quarterly EPS vs estimates
BioMarin Pharmaceutical beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: October 26, 2026 (estimate $1.13).
BMRN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B |
| Cost of revenue | $736.8M | $580.2M | $532.1M | $503.0M | $470.5M | $524.3M | $359.5M | $315.3M | $241.8M | $209.6M |
| Gross profit | $2.48B | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B | $1.34B | $1.18B | $1.07B | $907.2M |
| Research & development | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M | $628.1M | $715.0M | $696.3M | $610.8M | $661.9M |
| Sales, general & admin | $1.15B | $1.01B | $892.4M | $372.9M | $759.4M | $737.7M | $680.9M | $604.4M | $554.3M | $476.6M |
| Total operating expenses | $1.95B | $1.79B | $1.70B | $1.43B | $1.46B | $1.38B | $1.45B | $1.30B | $1.09B | $1.71B |
| Operating income | $533.5M | $484.2M | $185.8M | $161.0M | −$82.3M | −$43.4M | −$100.5M | −$123.5M | −$14.7M | −$803.4M |
| Interest income | $74.9M | $74.9M | $49.0M | $18.0M | $10.5M | $16.6M | $22.7M | $22.8M | $14.9M | $7.5M |
| Interest expense | $10.9M | $12.7M | $17.3M | $16.0M | $15.3M | $29.3M | $23.5M | $43.7M | $42.7M | $39.5M |
| Income before taxes | $482.5M | $541.8M | $188.6M | $149.6M | −$75.3M | −$49.0M | −$94.8M | −$142.7M | −$35.9M | −$831.0M |
| Income taxes | $133.6M | $114.9M | $20.9M | $8.0M | −$11.3M | −$903.0M | −$71.0M | −$65.5M | $81.2M | −$200.8M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | −$64.1M | $854.0M | −$23.8M | −$77.2M | −$117.0M | −$630.2M |
| EBITDA | $572.9M | $650.5M | $306.8M | $265.4M | $47.4M | $83.7M | $31.9M | −$3.4M | $91.0M | −$698.0M |
| EPS (diluted) | $3.15 | $3.14 | $1.78 | $1.57 | $0.96 | $1.38 | $0.91 | $0.55 | −$0.01 | −$0.57 |
| Gross margin | 77.1% | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% | 81.6% | 81.2% |
| Operating margin | 16.6% | 17.0% | 7.7% | 7.7% | −4.5% | −2.3% | −5.9% | −8.3% | −1.1% | −71.9% |
| Net margin | 10.8% | 15.0% | 6.9% | 6.8% | −3.5% | 45.9% | −1.4% | −5.2% | −8.9% | −56.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $989.7M | $766.2M | $874.6M | $776.1M | $825.4M | $745.1M | $747.3M | $745.7M | $712.0M | $648.8M | $646.2M | $581.3M |
| Cost of revenue | $202.8M | $195.0M | $295.1M | $140.1M | $150.1M | $151.6M | $136.1M | $188.5M | $130.5M | $125.2M | $135.5M | $128.0M |
| Gross profit | $786.9M | $571.2M | $579.5M | $636.0M | $675.3M | $593.6M | $611.2M | $557.3M | $581.6M | $523.7M | $510.7M | $453.3M |
| Research & development | $207.0M | $178.8M | $192.4M | $409.5M | $161.3M | $158.7M | $173.5M | $184.9M | $183.8M | $205.0M | $206.2M | $191.3M |
| Sales, general & admin | $395.5M | $258.3M | $802.1M | $268.4M | $232.3M | $206.1M | $266.6M | $253.5M | $263.0M | $225.9M | $275.0M | $172.6M |
| Total operating expenses | $676.0M | $441.6M | $500.1M | $682.7M | $398.4M | $369.7M | $449.8M | $443.4M | $461.1M | $435.2M | $496.5M | $422.8M |
| Operating income | $110.9M | $129.6M | $79.4M | −$46.7M | $276.9M | $223.9M | $161.4M | $113.9M | $120.5M | $88.5M | $14.2M | $30.5M |
| Interest income | $10.5M | $22.6M | $19.2M | $17.9M | $18.8M | $19.0M | $17.7M | $18.1M | $19.8M | $19.4M | $18.0M | $15.7M |
| Interest expense | $63.3M | $15.0M | $2.8M | $2.6M | $2.7M | $2.9M | $2.6M | $3.0M | $3.6M | $3.5M | $6.1M | $3.8M |
| Income before taxes | $61.4M | $141.2M | −$27.2M | −$26.3M | $297.9M | $238.1M | $169.6M | $134.4M | $132.1M | $105.5M | $19.3M | $41.7M |
| Income taxes | $16.6M | $35.7M | $19.4M | $4.4M | $57.3M | $52.4M | $44.7M | $28.4M | $25.0M | $16.9M | −$1.0M | $1.3M |
| Net income | $44.8M | $105.5M | −$46.6M | −$30.7M | $240.5M | $185.7M | $124.9M | $106.1M | $107.2M | $88.7M | $20.4M | $40.4M |
| EBITDA | $222.3M | $172.6M | −$3.9M | −$5.3M | $319.1M | $263.0M | $195.5M | $156.4M | $162.2M | $136.4M | $51.7M | $71.1M |
| EPS (diluted) | $0.90 | $0.76 | $0.46 | $0.12 | $1.44 | $1.13 | $0.92 | $0.55 | $0.96 | $0.71 | $0.18 | $0.46 |
| Gross margin | 79.5% | 74.6% | 66.3% | 82.0% | 81.8% | 79.7% | 81.8% | 74.7% | 81.7% | 80.7% | 79.0% | 78.0% |
| Operating margin | 11.2% | 16.9% | 9.1% | −6.0% | 33.5% | 30.0% | 21.6% | 15.3% | 16.9% | 13.6% | 2.2% | 5.3% |
| Net margin | 4.5% | 13.8% | −5.3% | −4.0% | 29.1% | 24.9% | 16.7% | 14.2% | 15.1% | 13.7% | 3.2% | 6.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BMRN's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BMRN financial results
In fiscal year 2025 (ended December 31, 2025), BioMarin Pharmaceutical reported revenue of $3.2 billion, up 12.9% from the year before. It had net income of $348.9 million (down 18.3%), a net profit margin of 10.8%. Diluted earnings per share came to $3.15. Over five years revenue grew at an average rate of 11.6% a year.
See the BMRN stock overview for the latest quote and news, or the BMRN chart for price history and technical indicators.
BMRN income statement FAQ
What is BioMarin Pharmaceutical's annual revenue?
BioMarin Pharmaceutical reported total revenue of $3.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 12.9% from $2.9 billion the previous year.
Is BioMarin Pharmaceutical profitable?
Yes. BioMarin Pharmaceutical reported net income of $348.9 million in fiscal 2025, a net profit margin of 10.8%; its operating margin was 16.6%.
What is BioMarin Pharmaceutical's gross margin?
BioMarin Pharmaceutical's gross margin was 77.1% in fiscal 2025: for every $100 of revenue, BioMarin Pharmaceutical kept $77 after the direct cost of its products and services.
How much does BioMarin Pharmaceutical spend on research and development?
BioMarin Pharmaceutical spent $921.9 million on research and development in fiscal 2025, 28.6% of revenue.
How fast is BioMarin Pharmaceutical growing?
Revenue grew 11.6% a year on average over the last five fiscal years, from $1.9 billion to $3.2 billion.
What are BioMarin Pharmaceutical's earnings per share?
BioMarin Pharmaceutical earned $3.15 per diluted share in fiscal 2025, compared with $3.14 a year earlier.
When will BioMarin Pharmaceutical report its next earnings?
BioMarin Pharmaceutical is expected to report results for the quarter ending September 30, 2026 on October 26, 2026 after the market closes.
When does BioMarin Pharmaceutical's fiscal year end?
BioMarin Pharmaceutical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.